Optimal Use of Epcoritamab in Follicular Lymphoma

Ruemu Birhiray, MD of Hematology Oncology of Indiana leads the continuation of a roundtable discussion on follicular lymphoma treatment. With Joshua Brody, MD, The Tisch Cancer Institute at Mount Sinai  and Julio Chavez, MD, Moffitt Cancer Center he discusses managing toxicities associated with epcoritamab combinations in follicular lymphoma, addressing key challenges and strategies for optimizing patient outcomes. The experts also examine the efficacy of epcoritamab-containing regimens, reviewing clinical data and insights on treatment responses, durability, and potential advancements in therapy.